Search our Trials

Search Results

Trial Number
Mechanism of Action
Drug Classifications
Target Required
Conditions
Site

24-05

Mechanism of Action

BG-68501 is a CDK2 Inhibitor

Drug Classifications

CDK2 Inhibitor

Conditions

Solid Tumor

Site

MCD
24-05
BG-68501 is a CDK2 Inhibitor
CDK2 Inhibitor
Solid Tumor
MCD

24-08

Mechanism of Action

RMC-6291 is a tri-complex inhibitor of the active GTP-bound state of the mutated KRASG12C protein RMC-6236 is a RASMULTI(ON) inhibitor

Drug Classifications

Small Molecule

Target Required

KRASG12C

Conditions

Solid Tumor

Site

MCD
24-08
RMC-6291 is a tri-complex inhibitor of the active GTP-bound state of the mutated KRASG12C protein RMC-6236 is a RASMULTI(ON) inhibitor
Small Molecule
KRASG12C
Solid Tumor
MCD

18-26

Mechanism of Action

Adagrasib is a potent, highly selective and orally available small molecule inhibitor of a form of KRAS that harbors an oncogenic substitution mutation (G12C). mutation...

Drug Classifications

Small Molecule Inhibitor

Target Required

KRAS G12C

Conditions

Solid Tumor

Site

MCD
18-26
Adagrasib is a potent, highly selective and orally available small molecule inhibitor of a form of KRAS that harbors an oncogenic substitution mutation (G12C). mutation...
Small Molecule Inhibitor
KRAS G12C
Solid Tumor
MCD

20-08

Mechanism of Action

TAK-676 is a synthetic cyclic dinucleotide (CDN) exhibiting highly selective binding and activation of STING pathway. 

Drug Classifications

Immunotherapy, targeted

Target Required

Not Required

Conditions

Colorectal Cancer, Head and Neck Cancer, Solid Tumor

Site

MCD
20-08
TAK-676 is a synthetic cyclic dinucleotide (CDN) exhibiting highly selective binding and activation of STING pathway. 
Immunotherapy, targeted
Not Required
Colorectal Cancer, Head and Neck Cancer, Solid Tumor
MCD

20-26

Mechanism of Action

GDC-0077 – PI3K inhibitor Idasanutlin – MDM2 protein antagonist Alectinib – ALK kinase inhibitor Trastuzumab Emtansine – HER2 antibody-drug conjugate Ipatasertib – AKT inhibitor Atezolizumab...

Drug Classifications

Antibody Drug Conjugate, Monoclonal Antibody, Small Molecule, Targeted Therapy

Target Required

[ROS1 fusion] tumors, [AKT1/2/3 mutant] tumors, [HER2 mutant] tumors, [MDM2-amplified, TP53 wild-type] tumors, [PIK3CA multiple mutant] tumors, [NTRK 1/2/3 fusion] tumors, [ALK fusion] tumors, TMB-high Solid Tumors

Conditions

Solid Tumor

Site

MCD
20-26
GDC-0077 – PI3K inhibitor Idasanutlin – MDM2 protein antagonist Alectinib – ALK kinase inhibitor Trastuzumab Emtansine – HER2 antibody-drug conjugate Ipatasertib – AKT inhibitor Atezolizumab...
Antibody Drug Conjugate, Monoclonal Antibody, Small Molecule, Targeted Therapy
[ROS1 fusion] tumors, [AKT1/2/3 mutant] tumors, [HER2 mutant] tumors, [MDM2-amplified, TP53 wild-type] tumors, [PIK3CA multiple mutant] tumors, [NTRK 1/2/3 fusion] tumors, [ALK fusion] tumors, TMB-high...
Solid Tumor
MCD

21-04

Mechanism of Action

AdAPT-001 is an oncolytic adenovirus that expresses a TGF-β (beta) trap fusion protein

Drug Classifications

Oncolytic virus

Target Required

Not Required

Conditions

Solid Tumor

Site

MCD
21-04
AdAPT-001 is an oncolytic adenovirus that expresses a TGF-β (beta) trap fusion protein
Oncolytic virus
Not Required
Solid Tumor
MCD

21-12

Mechanism of Action

ON 123300 is a small molecule, dual inhibitor of CDK4/6 and ARK5, a key enzyme controlling cellular energy homeostasis. Inhibition of ARK5 by ON 123300...

Drug Classifications

Small Molecule

Target Required

Not Required

Conditions

Solid Tumor

Site

MCD
21-12
ON 123300 is a small molecule, dual inhibitor of CDK4/6 and ARK5, a key enzyme controlling cellular energy homeostasis. Inhibition of ARK5 by ON 123300...
Small Molecule
Not Required
Solid Tumor
MCD

21-25

Mechanism of Action

BI 1810631 is an EGFR wild type sparing, selective HER2 inhibitor with potent inhibitory activity on all oncogenic HER2 mutations including the HER2 YVMA insertion...

Drug Classifications

Targeted Therapy

Target Required

HER2

Conditions

Lung Cancer (NSCLC), Solid Tumor

Site

MCD
21-25
BI 1810631 is an EGFR wild type sparing, selective HER2 inhibitor with potent inhibitory activity on all oncogenic HER2 mutations including the HER2 YVMA insertion...
Targeted Therapy
HER2
Lung Cancer (NSCLC), Solid Tumor
MCD

21-41

Mechanism of Action

ASP1570 is a small molecule immuno-oncology agent that is expected to act through the activation of immune cells in the tumor microenvironment.

Drug Classifications

Immunotherapy (Targeted), Small Molecule

Target Required

Not Required

Conditions

Lung Cancer (NSCLC), Skin Cancer/ Melanoma, Solid Tumor

Site

MCD
21-41
ASP1570 is a small molecule immuno-oncology agent that is expected to act through the activation of immune cells in the tumor microenvironment.
Immunotherapy (Targeted), Small Molecule
Not Required
Lung Cancer (NSCLC), Skin Cancer/ Melanoma, Solid Tumor
MCD

22-02

Mechanism of Action

IMP9064 is designed to inhibit the function of ATR, a component of the DNA damage repair system in all cells. Inhibition of DNA damage repair...

Drug Classifications

ATR inhibitor

Target Required

PARP& ATR

Conditions

Solid Tumor

Site

MCD
22-02
IMP9064 is designed to inhibit the function of ATR, a component of the DNA damage repair system in all cells. Inhibition of DNA damage repair...
ATR inhibitor
PARP& ATR
Solid Tumor
MCD

22-04

Mechanism of Action

BAL0891 is a small-molecule inhibitor of TTK and PLK1 . Inhibition of both kinases may lead to disruption of the spindle assembly checkpoint (SAC) driving...

Drug Classifications

Immunotherapy (Targeted), Small Molecule

Target Required

Not Required

Conditions

Solid Tumor

Site

MCD
22-04
BAL0891 is a small-molecule inhibitor of TTK and PLK1 . Inhibition of both kinases may lead to disruption of the spindle assembly checkpoint (SAC) driving...
Immunotherapy (Targeted), Small Molecule
Not Required
Solid Tumor
MCD

22-05

Mechanism of Action

MT-6402 may bind and kill both tumor and immune PD-L1 expressing cells in a manner consistent with SLTA mediated cellular cytotoxicity through ribosomal inactivation, independent...

Drug Classifications

6402 is a 514 amino acid cytotoxic fusion protein, comprised of 3 distinct polypeptide domains described here from N to C-terminus, targeting PD-L1

Target Required

PD-L1

Conditions

Head and Neck Cancer, Lung Cancer (NSCLC), Solid Tumor

Site

MCD
22-05
MT-6402 may bind and kill both tumor and immune PD-L1 expressing cells in a manner consistent with SLTA mediated cellular cytotoxicity through ribosomal inactivation, independent...
6402 is a 514 amino acid cytotoxic fusion protein, comprised of 3 distinct polypeptide domains described here from N to C-terminus, targeting PD-L1
PD-L1
Head and Neck Cancer, Lung Cancer (NSCLC), Solid Tumor
MCD

22-06

Mechanism of Action

ABSK061 inhibits FGFR2 and FGFR3. Inhibition of FGFR phosphorylation and signaling decreases cell viability. Selective inhibition avoids FGFR1 inhibition which potentially avoids side effects.

Drug Classifications

targeted

Target Required

FGFR2/3

Conditions

Breast Cancer, Endometrial Cancer, Gastric/GEJ Cancer, Head and Neck Cancer, Lung Cancer (NSCLC), Solid Tumor

Site

MCD
22-06
ABSK061 inhibits FGFR2 and FGFR3. Inhibition of FGFR phosphorylation and signaling decreases cell viability. Selective inhibition avoids FGFR1 inhibition which potentially avoids side effects.
targeted
FGFR2/3
Breast Cancer, Endometrial Cancer, Gastric/GEJ Cancer, Head and Neck Cancer, Lung Cancer (NSCLC), Solid Tumor
MCD

22-07

Mechanism of Action

IMM2902 is a bispecific antibody designed to bind to and block CD47, a cell surface protein that inhibits the immune response, and also bind to...

Drug Classifications

bispecific antibody

Target Required

CD47, ERBB2

Conditions

Breast Cancer, Esophageal Cancer, Gastric/GEJ Cancer, Solid Tumor

Site

MCD
22-07
IMM2902 is a bispecific antibody designed to bind to and block CD47, a cell surface protein that inhibits the immune response, and also bind to...
bispecific antibody
CD47, ERBB2
Breast Cancer, Esophageal Cancer, Gastric/GEJ Cancer, Solid Tumor
MCD

22-09

Mechanism of Action

CS5001 is a highly differentiated Antibody Drug Conjugate targeting ROR1. ROR1 is expressed across a variety of cancers, and may play an important role in...

Drug Classifications

Antibody Drug Conjugate, Targeted Therapy

Target Required

Not Required

Conditions

Breast Cancer, Lymphoma, Lymphoma (Diffuse Large B-cell), Solid Tumor

Site

MCD
22-09
CS5001 is a highly differentiated Antibody Drug Conjugate targeting ROR1. ROR1 is expressed across a variety of cancers, and may play an important role in...
Antibody Drug Conjugate, Targeted Therapy
Not Required
Breast Cancer, Lymphoma, Lymphoma (Diffuse Large B-cell), Solid Tumor
MCD

22-13

Mechanism of Action

UCT-03-008, CDK4/6 inhibitor, inhibits protein kinase from working and therefore, potentially stopping cancer cells to grow. Protein kinases are enzymes that are involved in the...

Drug Classifications

Small Molecule, Targeted Therapy

Target Required

Not Required

Conditions

Lung Cancer (NSCLC), Renal Cell Cancer, Solid Tumor

Site

MCD
22-13
UCT-03-008, CDK4/6 inhibitor, inhibits protein kinase from working and therefore, potentially stopping cancer cells to grow. Protein kinases are enzymes that are involved in the...
Small Molecule, Targeted Therapy
Not Required
Lung Cancer (NSCLC), Renal Cell Cancer, Solid Tumor
MCD

22-16

Mechanism of Action

BP1001 a liposome-incorporated Grb2 antisense oligodeoxynucleotide binds directly to and blocks Grb2 mRNA, thereby preventing Grb2 protein synthesis, leading to inhibition of cell proliferation of...

Drug Classifications

Small Molecule

Target Required

Not Required

Conditions

Endometrial Cancer, Ovarian/ Peritoneal/ Fallopian Tube Cancer, Solid Tumor

Site

MCD
22-16
BP1001 a liposome-incorporated Grb2 antisense oligodeoxynucleotide binds directly to and blocks Grb2 mRNA, thereby preventing Grb2 protein synthesis, leading to inhibition of cell proliferation of...
Small Molecule
Not Required
Endometrial Cancer, Ovarian/ Peritoneal/ Fallopian Tube Cancer, Solid Tumor
MCD

22-17

Mechanism of Action

RMC-6236 inhibits the RAS(ON) state of multiple RAS variants both mutant and wild-type proteins.

Drug Classifications

Small Molecule

Target Required

KRAS G12

Conditions

Colorectal Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Solid Tumor

Site

MCD
22-17
RMC-6236 inhibits the RAS(ON) state of multiple RAS variants both mutant and wild-type proteins.
Small Molecule
KRAS G12
Colorectal Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Solid Tumor
MCD

22-19

Mechanism of Action

NUV-868 is a small molecule bromodomain 2 (BD2)-selective bromodomain and extra-terminal domain (BET) inhibitor. The BET family of proteins have critical biological functions and are...

Drug Classifications

Small Molecule

Target Required

Not Required

Conditions

Breast Cancer, Colorectal Cancer, Ovarian/ Peritoneal/ Fallopian Tube Cancer, Pancreatic Cancer, Solid Tumor

Site

MCD
22-19
NUV-868 is a small molecule bromodomain 2 (BD2)-selective bromodomain and extra-terminal domain (BET) inhibitor. The BET family of proteins have critical biological functions and are...
Small Molecule
Not Required
Breast Cancer, Colorectal Cancer, Ovarian/ Peritoneal/ Fallopian Tube Cancer, Pancreatic Cancer, Solid Tumor
MCD

22-20

Mechanism of Action

PEEL-223 is a small molecule topoisomerase 1 (TOP1) inhibitor, which may lead to inhibiting the repair of single-strand DNA breaks, DNA replication, and tumor cell...

Drug Classifications

Small Molecule (Targeted)

Target Required

Not Required

Conditions

Solid Tumor

Site

MCD
22-20
PEEL-223 is a small molecule topoisomerase 1 (TOP1) inhibitor, which may lead to inhibiting the repair of single-strand DNA breaks, DNA replication, and tumor cell...
Small Molecule (Targeted)
Not Required
Solid Tumor
MCD

22-23

Mechanism of Action

ART0380 selectively targets and inhibits ATR activity and blocks the downstream phosphorylation of the serine/threonine protein kinase checkpoint kinase 1 (CHK1). This prevents ATR-mediated signaling,...

Drug Classifications

Small Molecule, Targeted Therapy

Target Required

ATM Gene Alterations likely to predict loss of ATM protein

Conditions

Solid Tumor

Site

MCD
22-23
ART0380 selectively targets and inhibits ATR activity and blocks the downstream phosphorylation of the serine/threonine protein kinase checkpoint kinase 1 (CHK1). This prevents ATR-mediated signaling,...
Small Molecule, Targeted Therapy
ATM Gene Alterations likely to predict loss of ATM protein
Solid Tumor
MCD

22-35

Mechanism of Action

MRT-2359 induces degradation of GSPT1 and associated downregulation of MYC transcription factors and their transcriptional outputs, which may lead to preferential anti-proliferative activity in MYC-driven...

Drug Classifications

Small Molecule

Target Required

Not Required

Conditions

Lung Cancer (NSCLC), Lung Cancer (SCLC), Solid Tumor

Site

MCD
22-35
MRT-2359 induces degradation of GSPT1 and associated downregulation of MYC transcription factors and their transcriptional outputs, which may lead to preferential anti-proliferative activity in MYC-driven...
Small Molecule
Not Required
Lung Cancer (NSCLC), Lung Cancer (SCLC), Solid Tumor
MCD

22-36

Mechanism of Action

E7386 inhibits beta-catenin and prevents the interaction of beta-catenin with its transcriptional coactivator, CREB (cAMP response element-binding) binding protein (CBP). This prevents binding of beta-catenin/CBP...

Drug Classifications

Small Molecule

Target Required

Not Required

Conditions

Colorectal Cancer, Endometrial Cancer, Hepatocellular Cancer, Solid Tumor

Site

MCD
22-36
E7386 inhibits beta-catenin and prevents the interaction of beta-catenin with its transcriptional coactivator, CREB (cAMP response element-binding) binding protein (CBP). This prevents binding of beta-catenin/CBP...
Small Molecule
Not Required
Colorectal Cancer, Endometrial Cancer, Hepatocellular Cancer, Solid Tumor
MCD

22-39

Mechanism of Action

JAB-2485 is a small molecule Aurora A inhibitor. Inhibition of Aurora A activity at the cellular level, induces apoptosis and inhibits tumor growth.

Drug Classifications

JAB-2485 is a small molecule Aurora A inhibitor

Target Required

Not Required

Conditions

Solid Tumor

Site

MCD
22-39
JAB-2485 is a small molecule Aurora A inhibitor. Inhibition of Aurora A activity at the cellular level, induces apoptosis and inhibits tumor growth.
JAB-2485 is a small molecule Aurora A inhibitor
Not Required
Solid Tumor
MCD

23-01

Mechanism of Action

Small molecule inhibitor of USP1

Drug Classifications

Small Molecule, Targeted Therapy

Target Required

Monotherapy – Tumor Biopsy Cohort: have the following deleterious homologous recombination repair (HRR+) tumor mutations: BRCA1, BRCA2, PALB2, RAD51, RAD51B, RAD51C, RAD51D, BARD1, BRIP1, FANCA, and NBN, as assessed by a CLIA-certified or equivalent laboratory.
Dose Escalation – Combination Therapy: HRR+ tumor mutations (BRCA1, BRCA2, PALB2, RAD51, RAD51B, RAD51C, RAD51D, BARD1, BRIP1, FANCA, and NBN)

Conditions

Ovarian/ Peritoneal/ Fallopian Tube Cancer, Solid Tumor

Site

MCD
23-01
Small molecule inhibitor of USP1
Small Molecule, Targeted Therapy
Monotherapy – Tumor Biopsy Cohort: have the following deleterious homologous recombination repair (HRR+) tumor mutations: BRCA1, BRCA2, PALB2, RAD51, RAD51B, RAD51C, RAD51D, BARD1, BRIP1, FANCA,...
Ovarian/ Peritoneal/ Fallopian Tube Cancer, Solid Tumor
MCD

23-02

Mechanism of Action

anti-GREM1 monoclonal antibody

Drug Classifications

Monoclonal Antibody

Target Required

Not Required

Conditions

Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric/GEJ Cancer, Lung Cancer (NSCLC), Prostate Cancer, Solid Tumor

Site

MCD
23-02
anti-GREM1 monoclonal antibody
Monoclonal Antibody
Not Required
Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric/GEJ Cancer, Lung Cancer (NSCLC), Prostate Cancer, Solid Tumor
MCD

23-04

Mechanism of Action

ASP1002 is anti-CLDN4 and anti-CD137 bispecific antibody

Drug Classifications

Bispecific Antibodies

Target Required

Not Required

Conditions

Solid Tumor

Site

MCD
23-04
ASP1002 is anti-CLDN4 and anti-CD137 bispecific antibody
Bispecific Antibodies
Not Required
Solid Tumor
MCD

23-05

Mechanism of Action

KT-253 is an MDM2 degrader

Drug Classifications

targeted

Target Required

Not Required

Conditions

Lymphoma, Solid Tumor

Site

MCD
23-05
KT-253 is an MDM2 degrader
targeted
Not Required
Lymphoma, Solid Tumor
MCD

23-06

Mechanism of Action

STX-478 is a PI3Kα small molecule inhibitor.

Drug Classifications

Small Molecule

Target Required

PI3Kα

Conditions

Breast Cancer, Solid Tumor

Site

MCD
23-06
STX-478 is a PI3Kα small molecule inhibitor.
Small Molecule
PI3Kα
Breast Cancer, Solid Tumor
MCD

23-09

Mechanism of Action

EO-3021 is an anti-CLDN18.2 antibody drug conjugate.

Drug Classifications

Antibody Drug Conjugate

Target Required

CLDN18.2

Conditions

Esophageal Cancer, Gastric/GEJ Cancer, Lung Cancer (NSCLC), Ovarian/ Peritoneal/ Fallopian Tube Cancer, Pancreatic Cancer, Solid Tumor

Site

MCD
23-09
EO-3021 is an anti-CLDN18.2 antibody drug conjugate.
Antibody Drug Conjugate
CLDN18.2
Esophageal Cancer, Gastric/GEJ Cancer, Lung Cancer (NSCLC), Ovarian/ Peritoneal/ Fallopian Tube Cancer, Pancreatic Cancer, Solid Tumor
MCD

23-10

Mechanism of Action

ART6043 is a Polθ inhibitor

Drug Classifications

Small Molecule

Target Required

*Genetic lesions known to cause loss of function of known DDR genes
*Hormone-receptor status, breast cancer gene (BRCA) mutation

Conditions

Breast Cancer, Solid Tumor

Site

MCD
23-10
ART6043 is a Polθ inhibitor
Small Molecule
*Genetic lesions known to cause loss of function of known DDR genes *Hormone-receptor status, breast cancer gene (BRCA) mutation
Breast Cancer, Solid Tumor
MCD

23-15

Mechanism of Action

HF158K1 is a HER2-targeting antibody liposome

Drug Classifications

Antibody Drug Conjugate (Monoclonal Antibody, Immunotherapy, targeted

Target Required

HER-2 positive or HER-2 low expression

Conditions

Solid Tumor

Site

MCD
23-15
HF158K1 is a HER2-targeting antibody liposome
Antibody Drug Conjugate (Monoclonal Antibody, Immunotherapy, targeted
HER-2 positive or HER-2 low expression
Solid Tumor
MCD

23-16

Mechanism of Action

INCB099280 is a PD-L1 inhibitor. Adagrasib is a KRAS inhibitor (G12C).

Drug Classifications

Small Molecule Immunotherapy

Target Required

Not Required

Conditions

Colorectal Cancer, Lung Cancer (NSCLC), Solid Tumor

Site

MCD
23-16
INCB099280 is a PD-L1 inhibitor. Adagrasib is a KRAS inhibitor (G12C).
Small Molecule Immunotherapy
Not Required
Colorectal Cancer, Lung Cancer (NSCLC), Solid Tumor
MCD

23-18

Mechanism of Action

LCB84 is an anti-TROP2 ADC

Drug Classifications

Antibody Drug Conjugate

Target Required

Not Required

Conditions

Anal Cancer, Breast Cancer, Colorectal Cancer, Endometrial Cancer, Gastric/GEJ Cancer, Lung Cancer (NSCLC), osteosarcoma, Ovarian/ Peritoneal/ Fallopian Tube Cancer, Pancreatic Cancer, Solid Tumor

Site

MCD
23-18
LCB84 is an anti-TROP2 ADC
Antibody Drug Conjugate
Not Required
Anal Cancer, Breast Cancer, Colorectal Cancer, Endometrial Cancer, Gastric/GEJ Cancer, Lung Cancer (NSCLC), osteosarcoma, Ovarian/ Peritoneal/ Fallopian Tube Cancer, Pancreatic Cancer, Solid Tumor
MCD

23-19

Mechanism of Action

RMC-9805 is a KRAS G12D inhibitor

Drug Classifications

Small Molecule (Targeted)

Target Required

KRASG12D

Conditions

Solid Tumor

Site

MCD
23-19
RMC-9805 is a KRAS G12D inhibitor
Small Molecule (Targeted)
KRASG12D
Solid Tumor
MCD

23-22

Mechanism of Action

GSK4524101 is a POLQ inhibitor

Drug Classifications

Small Molecule

Target Required

Not Required

Conditions

Solid Tumor

Site

MCD
23-22
GSK4524101 is a POLQ inhibitor
Small Molecule
Not Required
Solid Tumor
MCD

23-23

Mechanism of Action

BH3120 is a PD-L1 x 4-1BB Bispecific Monoclonal Antibody

Drug Classifications

Bispecific Antibodies

Target Required

PD-L1 positive expression

Conditions

Solid Tumor

Site

MCD
23-23
BH3120 is a PD-L1 x 4-1BB Bispecific Monoclonal Antibody
Bispecific Antibodies
PD-L1 positive expression
Solid Tumor
MCD

23-24

Mechanism of Action

FB849 is a HPK1 inhibitor

Drug Classifications

Immunotherapy (Targeted), Small Molecule

Target Required

Not Required

Conditions

Breast Cancer, Colorectal Cancer, Solid Tumor

Site

MCD
23-24
FB849 is a HPK1 inhibitor
Immunotherapy (Targeted), Small Molecule
Not Required
Breast Cancer, Colorectal Cancer, Solid Tumor
MCD

23-28

Mechanism of Action

AT-1965 is a CMTR2 inhibitor

Drug Classifications

Small Molecule (Targeted)

Target Required

Not Required

Conditions

Breast Cancer, Solid Tumor

Site

MCD
23-28
AT-1965 is a CMTR2 inhibitor
Small Molecule (Targeted)
Not Required
Breast Cancer, Solid Tumor
MCD

JIT-20210023

Mechanism of Action

n/a

Drug Classifications

n/a

Target Required

CDKN2A null, MTAP null

Conditions

Solid Tumor

Site

MCD
JIT-20210023
n/a
n/a
CDKN2A null, MTAP null
Solid Tumor
MCD

JIT-ENV-ONC-101

Mechanism of Action

ENV- 101, a potent Hedgehog (Hh) pathway inhibitor

Drug Classifications

n/a

Target Required

PTCH1 loss of function

Conditions

Solid Tumor

Site

MCD
JIT-ENV-ONC-101
ENV- 101, a potent Hedgehog (Hh) pathway inhibitor
n/a
PTCH1 loss of function
Solid Tumor
MCD

JIT-TSC-007

Mechanism of Action

n/a

Drug Classifications

n/a

Target Required

Inactivating Alterations in TSC1 or TSC2

Conditions

Solid Tumor

Site

MCD
JIT-TSC-007
n/a
n/a
Inactivating Alterations in TSC1 or TSC2
Solid Tumor
MCD

Connect With Us

Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.